Point of Care Molecular Diagnostics Market
Description
The global point of care molecular diagnostics market size reached USD 4.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 9.0 Billion by 2034, exhibiting a growth rate (CAGR) of 8.09% during 2026-2034. North America dominates the market owing to its improved healthcare infrastructure, strong presence of key industry players, and high adoption of innovative diagnostic technologies. The increasing incidence of infectious diseases paired with rapid development in healthcare facilities is significantly driving the market growth.
Point-of-care (POC) molecular diagnostics refer to tests performed by physicians to diagnose and detect infectious diseases. It includes hematology, pregnancy, fertility, infectious diseases, urinalysis testing kits, and cardiometabolic and glucose monitoring devices. POC molecular diagnostics is widely used for identifying infectious agents, minimal residual disease, and gastrointestinal disorders, monitoring hemoglobin and fecal occult blood, and determining a patient's ability to metabolize a drug or drug class. These tests offer faster results, reduce complications associated with mistreatment, and improve infection control measures. As a result, POC molecular diagnostics finds extensive applications in hospitals, intensive care units (ICUs), research institutes, clinics, decentralized laboratories, and homecare facilities.
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET TRENDS:
Rising Prevalence of Chronic and Infectious Diseases
The rising prevalence of diseases like cancer, diabetes, cardiovascular issues, and infectious outbreaks underscores the need for swift and precise diagnostic techniques. Point-of-care molecular diagnostics offer the benefit of prompt identification, allowing for timely medical action and efficient disease management. This is especially crucial for slowing disease progression, enhancing patient survival rates, and limiting the transmission of infectious diseases. In addition, the capability of point of care molecular diagnostics to track disease advancement and treatment efficacy enhances overall care management. With healthcare systems experiencing increased demand for diagnostic services from aging populations and changing health risks, point of care molecular diagnostics offer a scalable and effective solution. The ongoing necessity to tackle intricate health issues reinforces their acceptance, positioning disease prevalence as a key factor impelling the market growth.
Growing Geriatric Population
Elderly people are at greater risk for chronic illnesses, infectious diseases, and age-associated conditions, necessitating prompt and accurate diagnostics for effective treatment. As healthcare systems gear up to handle these increasing demands, the necessity for swift, precise, and readily available diagnostic tools is essential to facilitate early detection and intervention. The World Health Organization (WHO) emphasizes that by 2030, one in six people globally will be 60 years or older, and this figure is expected to reach 2.1 billion by 2050. Furthermore, the number of individuals aged 80 and over is predicted to grow three times, totaling 426 million by 2050. This demographic change is expected to exert significant strain on healthcare systems, highlighting the need for cutting-edge point-of-care molecular diagnostics to improve patient results, lessen hospital pressures, and facilitate effective, decentralized healthcare provision.
Emphasis on Decentralized Healthcare Delivery
With the growing healthcare needs, especially in rural, isolated, and resource-constrained areas, the need for diagnostic tools that can provide quick, accurate, and dependable results without relying on centralized lab facilities is becoming more vital. Point of care molecular diagnostics effectively tackle this issue by offering quick, on-site testing options that greatly minimize logistical obstacles like delays from sample transport, storage problems, and centralized processing delays. This decentralization guarantees that patients access earlier interventions and more precise treatment paths, leading to enhanced healthcare results and lower disease burdens. Additionally, as the focus on cost control and operational effectiveness grows, healthcare organizations are utilizing these technologies to improve patient management, boost workflow efficiency, and make the most of existing resources. Decentralized healthcare delivery remains a key growth factor for the point-of-care molecular diagnostics market by enhancing accessibility, speeding up turnaround times, and minimizing systemic inefficiencies.
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET GROWTH DRIVERS:
Demand for Affordable and Accurate Diagnostic Solutions
As healthcare systems strive to ensure broad access to dependable testing, affordable molecular platforms are gaining significance. These solutions merge high precision with lower operational costs, enabling wider accessibility in clinics, pharmacies, and even home environments. Affordable diagnostic technologies simplify workflows and decrease turnaround times by removing intricate sample preparation and lessening the requirement for specialized training. This equilibrium between accuracy and cost-effectiveness facilitates the substitution of unreliable testing techniques, leading to enhanced patient results and superior disease management. As healthcare systems focus on value-based care, the need for cost-effective and precise diagnostics is a vital factor propelling the market growth. In 2024, 3EO Health launched its CLIA-waived point-of-care molecular diagnostics platform in the US, offering COVID-19 testing under $20 with no sample prep. The compact 3TR system enabled affordable, high-efficiency testing in clinics and homes, aiming to replace antigen tests with molecular accuracy.
Advancements in Portable Diagnostic Technologies
Small and easy-to-use devices are facilitating dependable testing beyond conventional lab environments, broadening access to essential diagnostic services in urban and rural regions. These advancements deliver quick, precise outcomes, aiding prompt clinical choices and minimizing the wait times linked to centralized testing centers. Improved portability enables healthcare professionals to perform testing in various settings, ranging from community health facilities to distant clinics, thus expanding healthcare access and enhancing disease management results. The simplicity of deployment, paired with low infrastructure needs, enables portable diagnostics to be highly versatile for extensive usage. Enhancing efficiency, scalability, and accessibility, innovations in portable molecular diagnostics bolster the market’s contribution to advancing global healthcare delivery and guaranteeing fair access to vital testing. In 2024, India’s Truenat, a point-of-care molecular diagnostics platform by Molbio, was recognized at the 77th World Health Assembly for its role in combating TB. The portable, battery-operated PCR device delivers rapid, high-accuracy results in under an hour and is widely deployed across India.
Integration with Digital Health and Data Analytics
The combination of point-of-care molecular diagnostics with digital health platforms and sophisticated data analytics is contributing to the market growth. Contemporary connectivity capabilities, such as cloud data storage, mobile health apps, and electronic health record (EHR) integration, enable the smooth transfer, access, and monitoring of diagnostic results throughout healthcare networks. This interoperability enhances clinical decision-making by enabling healthcare providers to obtain real-time data, monitor disease progression, and more efficiently coordinate personalized treatment plans. Additionally, analytics-driven insights support population health management by identifying disease trends, predicting potential outbreaks, and improving the allocation of healthcare resources. Furthermore, integrating diagnostic technologies with telemedicine services and remote monitoring systems allows patients in rural and underserved regions to access prompt, precise, and ongoing care. This cohesive ecosystem promotes enhanced precision and operational effectiveness, alongside increased patient involvement and adherence, supporting the adoption of point-of-care molecular diagnostics globally.
KEY MARKET SEGMENTATION:
IMARC Group provides an analysis of the key trends in each sub-segment of the global point of care molecular diagnostics market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on product and service, technology, application and end user.
Breakup by Product and Service:
The report has also provided a comprehensive analysis of the competitive landscape in the global point of care molecular diagnostics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:
KEY QUESTIONS ANSWERED IN THIS REPORT
1. What was the size of the global point of care molecular diagnostics market in 2025?
2. What is the expected growth rate of the global point of care molecular diagnostics market during 2026-2034?
3. What are the key factors driving the global point of care molecular diagnostics market?
4. What has been the impact of COVID-19 on the global point of care molecular diagnostics market?
5. What is the breakup of the global point of care molecular diagnostics market based on the product and service?
6. What is the breakup of the global point of care molecular diagnostics market based on the technology?
7. What is the breakup of the global point of care molecular diagnostics market based on application?
8. What are the key regions in the global point of care molecular diagnostics market?
9. Who are the key players/companies in the global point of care molecular diagnostics market?
Point-of-care (POC) molecular diagnostics refer to tests performed by physicians to diagnose and detect infectious diseases. It includes hematology, pregnancy, fertility, infectious diseases, urinalysis testing kits, and cardiometabolic and glucose monitoring devices. POC molecular diagnostics is widely used for identifying infectious agents, minimal residual disease, and gastrointestinal disorders, monitoring hemoglobin and fecal occult blood, and determining a patient's ability to metabolize a drug or drug class. These tests offer faster results, reduce complications associated with mistreatment, and improve infection control measures. As a result, POC molecular diagnostics finds extensive applications in hospitals, intensive care units (ICUs), research institutes, clinics, decentralized laboratories, and homecare facilities.
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET TRENDS:
Rising Prevalence of Chronic and Infectious Diseases
The rising prevalence of diseases like cancer, diabetes, cardiovascular issues, and infectious outbreaks underscores the need for swift and precise diagnostic techniques. Point-of-care molecular diagnostics offer the benefit of prompt identification, allowing for timely medical action and efficient disease management. This is especially crucial for slowing disease progression, enhancing patient survival rates, and limiting the transmission of infectious diseases. In addition, the capability of point of care molecular diagnostics to track disease advancement and treatment efficacy enhances overall care management. With healthcare systems experiencing increased demand for diagnostic services from aging populations and changing health risks, point of care molecular diagnostics offer a scalable and effective solution. The ongoing necessity to tackle intricate health issues reinforces their acceptance, positioning disease prevalence as a key factor impelling the market growth.
Growing Geriatric Population
Elderly people are at greater risk for chronic illnesses, infectious diseases, and age-associated conditions, necessitating prompt and accurate diagnostics for effective treatment. As healthcare systems gear up to handle these increasing demands, the necessity for swift, precise, and readily available diagnostic tools is essential to facilitate early detection and intervention. The World Health Organization (WHO) emphasizes that by 2030, one in six people globally will be 60 years or older, and this figure is expected to reach 2.1 billion by 2050. Furthermore, the number of individuals aged 80 and over is predicted to grow three times, totaling 426 million by 2050. This demographic change is expected to exert significant strain on healthcare systems, highlighting the need for cutting-edge point-of-care molecular diagnostics to improve patient results, lessen hospital pressures, and facilitate effective, decentralized healthcare provision.
Emphasis on Decentralized Healthcare Delivery
With the growing healthcare needs, especially in rural, isolated, and resource-constrained areas, the need for diagnostic tools that can provide quick, accurate, and dependable results without relying on centralized lab facilities is becoming more vital. Point of care molecular diagnostics effectively tackle this issue by offering quick, on-site testing options that greatly minimize logistical obstacles like delays from sample transport, storage problems, and centralized processing delays. This decentralization guarantees that patients access earlier interventions and more precise treatment paths, leading to enhanced healthcare results and lower disease burdens. Additionally, as the focus on cost control and operational effectiveness grows, healthcare organizations are utilizing these technologies to improve patient management, boost workflow efficiency, and make the most of existing resources. Decentralized healthcare delivery remains a key growth factor for the point-of-care molecular diagnostics market by enhancing accessibility, speeding up turnaround times, and minimizing systemic inefficiencies.
POINT OF CARE MOLECULAR DIAGNOSTICS MARKET GROWTH DRIVERS:
Demand for Affordable and Accurate Diagnostic Solutions
As healthcare systems strive to ensure broad access to dependable testing, affordable molecular platforms are gaining significance. These solutions merge high precision with lower operational costs, enabling wider accessibility in clinics, pharmacies, and even home environments. Affordable diagnostic technologies simplify workflows and decrease turnaround times by removing intricate sample preparation and lessening the requirement for specialized training. This equilibrium between accuracy and cost-effectiveness facilitates the substitution of unreliable testing techniques, leading to enhanced patient results and superior disease management. As healthcare systems focus on value-based care, the need for cost-effective and precise diagnostics is a vital factor propelling the market growth. In 2024, 3EO Health launched its CLIA-waived point-of-care molecular diagnostics platform in the US, offering COVID-19 testing under $20 with no sample prep. The compact 3TR system enabled affordable, high-efficiency testing in clinics and homes, aiming to replace antigen tests with molecular accuracy.
Advancements in Portable Diagnostic Technologies
Small and easy-to-use devices are facilitating dependable testing beyond conventional lab environments, broadening access to essential diagnostic services in urban and rural regions. These advancements deliver quick, precise outcomes, aiding prompt clinical choices and minimizing the wait times linked to centralized testing centers. Improved portability enables healthcare professionals to perform testing in various settings, ranging from community health facilities to distant clinics, thus expanding healthcare access and enhancing disease management results. The simplicity of deployment, paired with low infrastructure needs, enables portable diagnostics to be highly versatile for extensive usage. Enhancing efficiency, scalability, and accessibility, innovations in portable molecular diagnostics bolster the market’s contribution to advancing global healthcare delivery and guaranteeing fair access to vital testing. In 2024, India’s Truenat, a point-of-care molecular diagnostics platform by Molbio, was recognized at the 77th World Health Assembly for its role in combating TB. The portable, battery-operated PCR device delivers rapid, high-accuracy results in under an hour and is widely deployed across India.
Integration with Digital Health and Data Analytics
The combination of point-of-care molecular diagnostics with digital health platforms and sophisticated data analytics is contributing to the market growth. Contemporary connectivity capabilities, such as cloud data storage, mobile health apps, and electronic health record (EHR) integration, enable the smooth transfer, access, and monitoring of diagnostic results throughout healthcare networks. This interoperability enhances clinical decision-making by enabling healthcare providers to obtain real-time data, monitor disease progression, and more efficiently coordinate personalized treatment plans. Additionally, analytics-driven insights support population health management by identifying disease trends, predicting potential outbreaks, and improving the allocation of healthcare resources. Furthermore, integrating diagnostic technologies with telemedicine services and remote monitoring systems allows patients in rural and underserved regions to access prompt, precise, and ongoing care. This cohesive ecosystem promotes enhanced precision and operational effectiveness, alongside increased patient involvement and adherence, supporting the adoption of point-of-care molecular diagnostics globally.
KEY MARKET SEGMENTATION:
IMARC Group provides an analysis of the key trends in each sub-segment of the global point of care molecular diagnostics market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on product and service, technology, application and end user.
Breakup by Product and Service:
- Assays and Kits
- Instruments and Analyzers
- Software and Services
- Polymerase Chain Reaction (PCR)
- Hybridization
- DNA sequencing
- Microarray
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Others
- Infectious Diseases
- Oncology
- Hematology
- Prenatal Testing
- Endocrinology
- Others
- Physicians’ Offices
- Hospitals and ICUs
- Research Institutes
- Others
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of the competitive landscape in the global point of care molecular diagnostics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:
- Abbott Laboratories
- Becton, Dickinson and Company
- binx health, inc.
- Cepheid (Danaher Corporation)
- Co-Diagnostics Inc.
- F. Hoffmann-La Roche Ltd
- Meridian Bioscience
- Molbio Diagnostics Limited
- QuantuMDx Group Limited
- Thermo Fisher Scientific Inc.
- Visby Medical Inc.
KEY QUESTIONS ANSWERED IN THIS REPORT
1. What was the size of the global point of care molecular diagnostics market in 2025?
2. What is the expected growth rate of the global point of care molecular diagnostics market during 2026-2034?
3. What are the key factors driving the global point of care molecular diagnostics market?
4. What has been the impact of COVID-19 on the global point of care molecular diagnostics market?
5. What is the breakup of the global point of care molecular diagnostics market based on the product and service?
6. What is the breakup of the global point of care molecular diagnostics market based on the technology?
7. What is the breakup of the global point of care molecular diagnostics market based on application?
8. What are the key regions in the global point of care molecular diagnostics market?
9. Who are the key players/companies in the global point of care molecular diagnostics market?
Table of Contents
140 Pages
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Point of Care Molecular Diagnostics Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Product and Service
- 6.1 Assays and kits
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Instruments and Analyzers
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Software and Services
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 7 Market Breakup by Technology
- 7.1 Polymerase Chain Reaction (PCR)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Hybridization
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 DNA sequencing
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Microarray
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
- 8 Market Breakup by Application
- 8.1 Infectious Diseases
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Oncology
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Hematology
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Prenatal Testing
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Endocrinology
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 8.6 Others
- 8.6.1 Market Trends
- 8.6.2 Market Forecast
- 9 Market Breakup by End User
- 9.1 Physicians’ Offices
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Hospitals and ICUs
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Research Institutes
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
- 10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
- 11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
- 12 Value Chain Analysis
- 13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
- 14 Price Analysis
- 15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Becton, Dickinson and Company
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 binx health, inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.4 Cepheid (Danaher Corporation)
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Co-Diagnostics Inc.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.6 F. Hoffmann-La Roche Ltd
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.7 Meridian Bioscience
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Molbio Diagnostics Limited
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.9 QuantuMDx Group Limited
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Thermo Fisher Scientific Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Visby Medical Inc.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
